EZH2 and telomere syndrome: To address these potential resistance mechanisms, PEMBROSARC is currently assessing the addition of an anti-IDO1, TLR4 agonist or EZH2 inhibitor to the combined pembrolizumab and metronomic cyclophosphamide treatment in advanced STS patients (NCT02406781) [96].